LOXL2 and osteosarcoma: Furthermore, pretreatment with ERK, p38, and JNK inhibitors or siRNAs reversed the FGF-23-induced suppression of miR-4463 and the increase in LOXL2 expression, indicating that the FGF-23/miR-4463/LOXL2 axis contributes to the regulation of osteosarcoma metastasis.